Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial of AVP-786 for intermittent explosive disorder was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Explosive Disorder

Drugs mentioned

• AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Intermittent Explosive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2022-05-24